Rebecca Pedersen, MD
Family Medicine · Freeport, ILNPI 1770556672
Payments from drug & device makers
Across 100 payments — averaging $16.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$374
- E.r. Squibb & Sons, L.L.C.$205
- Amgen$197
- AbbVie$146
- Novo Nordisk$120
- Johnson & Johnson$53
- plus $569 from 20 others
What the payments were for
- Food & beverage$1,664100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 26 | $374 |
| E.r. Squibb & Sons, L.L.C. | 12 | $205 |
| Amgen | 12 | $197 |
| AbbVie | 8 | $146 |
| Novo Nordisk | 7 | $120 |
| Johnson & Johnson | 3 | $53 |
| Dexcom, Inc. | 2 | $47 |
| AstraZeneca | 3 | $47 |
| GSK | 2 | $46 |
| Lilly USA, LLC | 3 | $37 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $34 |
| Boehringer Ingelheim | 2 | $33 |
| Insulet Corporation | 1 | $33 |
| Bayer | 2 | $32 |
| Astellas Pharma US Inc | 2 | $31 |
| Corcept Therapeutics | 1 | $31 |
| Kowa Pharmaceuticals America, Inc. | 2 | $30 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Exact Sciences | 1 | $23 |
| Cranial Technologies, Inc | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $15 |
| Ascensia Diabetes Care US Inc. | 1 | $15 |
| Merck | 1 | $14 |
How this compares
$1,664 in reported general payments places this provider in the 80th percentile of 4,116 family medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 71 | $77,230 |
| OzempicSemaglutide | 42 | $58,231 |
| EliquisApixaban | 67 | $45,272 |
| FarxigaDapagliflozin Propanediol | 36 | $35,317 |
| MounjaroTirzepatide | 21 | $24,584 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $11,279 |
| MyrbetriqMirabegron | 25 | $8,569 |
| Tresiba Flextouch U-100Insulin Degludec | 16 | $7,840 |
| DapagliflozinDapagliflozin Propanediol | 15 | $4,310 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $3,661 |
| EntrestoSacubitril/Valsartan | 11 | $3,396 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $2,826 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 34 | $2,141 |
| Metoprolol Succinate | 179 | $2,022 |
| Potassium Chloride | 119 | $1,954 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $53 | $77,23071 claims |
| Novo NordiskOzempic | $120 | $58,23142 claims |
| PfizerEliquis | $374 | $45,27267 claims |
| AstraZenecaFarxiga | $47 | $35,31736 claims |
| Lilly USA, LLCMounjaro | $37 | $24,58421 claims |
| GSKTrelegy Ellipta | $46 | $11,27914 claims |
| Astellas Pharma US IncMyrbetriq | $31 | $8,56925 claims |
| AbbVieSynthroid | $146 | $1,55519 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,116 family medicine providers in Illinois.
Other family medicine in Freeport
- Daniel BruneCreve Coeur$15M
- Ali BajwaSpringfield$5.8M
- John ElsenEvergreen Park$5M
- Manohar JethaniBerwyn$4.9M
- Tiffany NguyenSkokie$3.9M
- Bradley TorphyChicago$3M
- Diana WidicusRochester$2.6M
- Nicholas WeberEureka$2.5M
- Stanley KochMorton$2.3M
- Mark ChristensenNew Lenox$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.